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OBJECTIVE: The cost-effectiveness of heart failure (HF) disease
management depends on avoiding future high costs. Prospec-
tively identifying HF patients who are likely to incur high costs
would be beneﬁcial. METHODS: We used a 100% sample of
1,363,977 Medicare beneﬁciaries hospitalized with a primary
diagnosis of HF (ICD-9-CM codes 428.x, 402.x1, 404.x1,
404.x3) between 2001 and 2004. The earliest HF hospitalization
for each beneﬁciary was considered the index. We summed Medi-
care payments for rehospitalizations in the year following the
index hospitalization, adjusted costs to 2001 dollars, and created
a binary variable, with patients in the 4th quartile (>$16,500)
deﬁned as “high cost.” Comorbidities and risks were obtained
from the index claim and from inpatient claims in the prior year.
Logistic regression was used to predict high cost status in a 75%
random derivation sample; the model was validated in the
remaining 25%. We evaluated the calibration and discrimination
of the model in both samples and reﬁt the model on the entire
sample. RESULTS: Average Medicare payments in the year
following index hospitalization were $38,300 (SD $29,146)
among high cost patients and $4272 (SD $4857) among patients
in the lower 3 quartiles. Inpatient cost in the prior year was the
strongest predictor of inpatient cost in the subsequent year (OR
2.31, 95% CI: 2.27–2.35 for prior year inpatient costs >$16,500
vs. no inpatient costs in the prior year.) In both the derivation and
validation cohorts, 11% of patients in the lowest decile and 45%
of patients in the highest decile were high cost. The model was
well-calibrated. The c-statistic was 0.65 for both the derivation
and validation cohorts. CONCLUSION: There is limited ability
to predict high cost HF patients using claims data alone. Future
studies should assess the value of incorporating clinical variables.
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IMPACT OF ADOPTION OF NEW ANTIHYPERTENSIVE DRUGS
ONTHE HEALTH CARE UTILIZATION IN HYPERTENSIVE
PATIENTS
Ganguli A, Hong SH,Wingate L
University of Tennessee, Memphis,TN, USA
OBJECTIVE: This study aims to analyze the hypothesis that
utilization of newer medications is associated with decreased
health care utilization and increased quality of life in patients
with hypertension. METHODS: This is a retrospective follow up
study of patients identiﬁed as hypertensive (ICD-9-CM codes
401–405) and prescribed at least one antihypertensive medica-
tion during round one of 1999 MEPS database. Antihypertensive
drugs approved by FDA during the years 1996, 1997 and 1998
were deﬁned as ‘new antihypertensive drugs’. New drug adopters
(NDA) were those hypertensive patients who were prescribed
atleast one new antihypertensive medication. The total health
care expenditure and the non-prescription health care expendi-
ture were taken as markers for health care utilization and the
number of ER visits was a marker for quality of life of a patient.
RESULTS: Fourteen new antihypertensive drugs were approved
by FDA during the year 1996 (3), 1997 (7) and 1998 (4). A total
of 1149 (un-weighed) patients were identiﬁed as the study popu-
lation of which 63 (5.88%) patients were identiﬁed as NDA’s.
Females comprised 66.67% (42) in NDA’s and 49.82% (534) in
non-NDA’s. The New drug adopters were found to spend $637
& $675 more on total health care expenditure and on non-
prescriptions expenses respectively as compared to non-NDA’s.
Also NDA’s had 0.124 more ER visits as compared to non-
NDA’s. These results were statistically insigniﬁcant at 0.05 level
when adjusted for age, gender, income, race, ethnicity, number of
co-morbid conditions and insurance status. CONCLUSION: No
relation was found between the total health care utilization and
adoption of newer antihypertensive medications on aggregate
level. This signiﬁes the need to scrutinize the pharmacoeconomic
evaluation of each new drug before acceptance by physicians and
pharmacy managers.
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OBJECTIVES: Assessment of point of care devices (POCs) that
measure INR does not typically include the impact of measure-
ment error on clinical decision-making. This study determined
the effect of POC measurement error on warfarin dosing
decisions, and how this effect varies over the INR scale.
METHODS: For each patient, INR was simultaneously mea-
sured using two different POC devices and standard laboratory
techniques. Clinicians blinded to INR measurement technique
were asked to state a warfarin dosing decision for each INR
value. The difference between each POC-derived INR and the
laboratory standard measure were recorded for each patient, as
were differences in warfarin dosing decisions based on the POC
devices versus laboratory standard measures. RESULTS: A total
of 202 patients on warfarin therapy were enrolled. Overall, the
POC devices resulted in different warfarin dosing decisions com-
pared to the laboratory standard in 114 of 404 instances (28%,
95% CI: 24–33%). Discordant dosing decisions resulting from
POC and laboratory measures were most common when the
laboratory INR was between 1.5–1.99 (40/92, 43%, 95% CI:
33–55%) and 3–3.49 (15/36, 42%, 95% CI: 26–59%). Rela-
tively small amounts of measurement error from the POC devices
resulted in different warfarin dosing decisions between the labo-
ratory and POCs at speciﬁc intervals in the INR scale. For
example, overestimation of INR by the POC by 0.2–0.39 INR
units resulted in discordant warfarin dosing decisions in 44% of
instances when the laboratory INR was between 1.5–1.99.
CONCLUSIONS: Measurement error in POC devices leads to
different warfarin doses in a high proportion of cases. A rela-
tively small amount of measurement error can result in different
warfarin dosing decisions if it occurs at speciﬁc intervals on the
INR scale. Investigators and regulators should consider the
varying effect of measurement error along the INR scale and its
impact on clinical decision-making when evaluating POCs.
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OBJECTIVE: Estimating the cost-effectiveness of disease man-
agement programs requires a comprehensive assessment of per-
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sonnel and patient time. Assessments at a single time point may
under- or overestimate the time required to perform related
activities. In this study, we use data from a large clinical trial of
exercise therapy in patients with heart failure to evaluate whether
there is evidence of a learning curve with regard to time spent on
non-exercise activities across 36 supervised exercise training ses-
sions across 12 weeks. METHODS: As part of the economic
evaluation planned alongside the NIH-sponsored HF-ACTION
trial, a Provider and Patient Time Assessment Survey was admin-
istered across 9 study sites representing a subset of 56 patients.
The survey was designed to assess provider time with and
without the patient, pre- and post-exercise, to account for a
variety of related tasks (e.g. pulling charts, patient education,
scheduling, etc.). Linear growth models were used to model the
trajectory change of time spent on ‘non-exercise’ activities across
36 visits. RESULTS: Data were available for 39 (69.6%) patients
who completed all 36 exercise sessions, 7 (12.5%) patients who
were still enrolled in ongoing exercise training, and 10 (17.9%)
patients who discontinued exercise training. The average non-
exercise time associated with supervised training was 30.3
(SD = 19.8) minutes, comprised of 20.6 minutes spent with
patients and 9.5 minutes without patients. After adjusting for
whether warm-up/cool-down activities were included, the total
time spent on non-exercise activities decreased signiﬁcantly
(parameter estimate: -1.04 minutes/week; p = 0.007), with
approximately equal reductions in time with patients (-0.57
minutes/week; p = 0.038), and without patients (-0.65 minutes/
week; p = 0.058) over 12 weeks. CONCLUSION: Our analysis
suggests that providers and patients experienced efﬁciency gains
in regard to time spent on activities associated with supervised
exercise training. These results demonstrate the potential impor-
tance of comprehensive time assessment when evaluating disease
management programs.
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OBJECTIVE: The goal of the study was to test the effects of
step therapy on pharmaceutical and medical utilization and
costs. This study examined the effect of step therapy for anti-
depressant and antihypertensive medications. METHODS: The
data was extracted from the MarketScan database, representing
the health care experience of enrollees in employer-sponsored,
commercial health plans. The sample consisted of employees
and dependents of 4 employers (2-step therapy and 2 controls)
who were continuously enrolled in the MarketScan database
from 2003 through the third quarter of 2006 and who used
antidepressants (N = 15,552 step therapy; N = 45,244 control)
or antihypertensives (N = 11,851 step therapy; N = 30,822
control) at least once during the study period. An analytic ﬁle
was created using a panel data framework, yielding 15 obser-
vations or quarters of data per patient. Chi-square and Stu-
dent’s t-tests were computed to compare demographic and
clinical characteristics as well as outcome variables between the
step therapy and comparison groups after step therapy had been
implemented for plans with step therapy. Multivariate general-
ized estimating equation (GEE) models were used to estimate
the effects of step therapy on spending and utilization while
controlling for important covariates and adjusting for clustering
by patient. RESULTS: Step therapy had the intended effect of
increasing generic prescribing and lowering brand prescribing.
Overall, medication costs were reduced in the step therapy plans
in the initial period following implementation. However, inpa-
tient, outpatient, and emergency room utilization and costs
were higher in the step therapy plans after step therapy was
implemented relative to the comparison groups. Medication
discontinuation rates for the targeted drugs increased in step
therapy plans. CONCLUSION: Implementation of step therapy
produces intended and unintended results. The intended results
of reducing drug costs are found to co-occur with unintended
results that may adversely affect patients as evidenced by higher
ER and inpatient utilization.
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OBJECTIVE: In this study, cost-effectiveness of different doses
of Atorvastatin, Pravastatin, Rosuvastatin and Simvastatin are
compared. The results are used to evaluate if prescription deci-
sions follow willingness to pay. METHODS: Incremental cost-
effectiveness ratios (ICERs) were calculated using a model to be
published in Value in Health. However, for this analysis, we used
efﬁcacy estimates from a meta-analysis that compared several
statins across dose ranges. Furthermore, we considered two sce-
narios. In scenario 1, doses are doubled after 12 weeks of treat-
ment if the LDL level is over 115 mg/dL; in scenario 2, the dose
is ﬁxed. For the analysis of prescription patterns and costs per
dose, we used ofﬁcial data. RESULTS: Results show that, in both
scenarios, Pravastatin 10 mg and 20 mg and Atorvastatin 10 mg
are dominated. Taking Simvastatin 10 mg as reference, the ICER
of Simvastatin 20 mg in scenario 1 is €203,780 and the ICER of
Rosuvastatin 10 mg is €108,293, while the ICER of Rosuvastatin
10 mg compared to Simvastatin 20 mg is €61,670. In scenario 2,
the ICERs of Simvastatin 20 mg and Rosuvastatin 10 mg are
€199.933 and €61.238, respectively, while Rosuvastatin 10 mg
dominates Simvastatin 20 mg. In both cases the Simvastatin
20 mg ICER is well above the €50.000 per life year gained
threshold. However, Simvastatin 20 mg is the most prescribed
alternative in Portugal. In fact, during 2006 its market share was
around 66%, while Simvastatin 10 mg accounted just for 2%
and Rosuvastatin 10 mg for 12%. Future research will show how
results change with the market launch of Rosuvastatin 5 mg.
CONCLUSION: Doctors are not inﬂuenced by economic evalu-
ation when prescribing statins. Results show that Simvastatin
10 mg should be used as ﬁrst line and Rosuvastatin 10 mg as
second line strategies. Most probably, the high market share of
Simvastatin 20 mg reﬂects the “ﬁrst mover” advantage in the
market.
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THE EFFECTIVENESS OF A PATIENT AND PHYSICIAN
EDUCATIONAL PROGRAM IN INITIATING STATINTHERAPY
AMONG DIABETICS
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OBJECTIVE: To evaluate the effectiveness of a patient- and
physician-directed communication program to consider initia-
tion of statin therapy among diabetics. METHODS: Educa-
tional letters were sent to physicians and patients from a large
commercial health plan. Physician- and patient-directed letters
were sent to 593 and 579 patients respectively. Letters to the
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